• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Azenta Inc.

    5/30/25 4:15:02 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email
    SD 1 azta20250530_sd.htm FORM SD azta20250530_sd.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     


     

    FORM SD

     

    Specialized Disclosure Report

     

    AZENTA, INC.

     

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware

     

    0‑25434

     

    04‑3040660

    (State or Other Jurisdiction of Incorporation)

     

    (Commission File Number)

     

    (IRS Employer Identification No.)

     

     

    200 Summit Drive, 6th Floor, Burlington, MA

     

    01803

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

     

    Ephraim Starr

    (888) 229-3682

    Name and telephone number, including area code, of the person to contact in connection with this report.

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

    ☒

    Rule 13p‑1 under the Securities Exchange Act (17 CFR 240.13p‑1) for the reporting period from January 1 to December 31, 2024.

     

     

     

     

    Section 1 - Conflict Minerals Disclosure

     

    Item 1.01 Conflict Minerals Disclosure and Report

     

    A copy of the Conflict Minerals Report of Azenta, Inc. for calendar year 2024 is filed as Exhibit 1.01 to this Form SD and is publicly available on Azenta, Inc.’s website at https://investors.azenta.com/corporate-governance.

     

    Item 1.02 Exhibit

     

    The Conflict Minerals Report required by Item 1.01 is filed as Exhibit 1.01 to this Form SD.

     

    Section 2 – Exhibits

     

    Item 2.01 Exhibits

     

    The following Exhibit is filed as a part of this report:

     

    Exhibit 1.01

    Conflict Minerals Report for the year ended December 31, 2024

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    AZENTA, INC.

       
         

    /s/ Ephraim Starr

       

    Ephraim Starr

     

    Date: May 30, 2025

    Senior Vice President, General Counsel and
    Secretary

       

     

     
    Get the next $AZTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    7/19/2023Mkt Perform
    Raymond James
    5/10/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    2/9/2023$65.00 → $60.00Overweight → Equal-Weight
    Stephens
    1/3/2023$60.00 → $62.00Outperform → In-line
    Evercore ISI
    3/31/2022$106.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and General Manager, Genom Zhou Ginger bought $19,132 worth of Common (417 units at $45.88), increasing direct ownership by 2% to 27,916 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/4/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • President and CEO Marotta John was granted 83,622 units of Common and bought $552,904 worth of Common (13,967 units at $39.59), increasing direct ownership by 2,982% to 100,862 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:16 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Cornog William L bought $495,000 worth of Common (12,500 units at $39.60) (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:11 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Azenta upgraded by Stephens with a new price target

      Stephens upgraded Azenta from Equal-Weight to Overweight and set a new price target of $60.00 from $50.00 previously

      12/18/24 7:25:24 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Jefferies initiated coverage on Azenta with a new price target

      Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00

      4/4/24 7:29:19 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • B. Riley Securities reiterated coverage on Azenta with a new price target

      B. Riley Securities reiterated coverage of Azenta with a rating of Buy and set a new price target of $79.00 from $61.00 previously

      2/1/24 8:17:35 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    SEC Filings

    See more
    • SEC Form SD filed by Azenta Inc.

      SD - Azenta, Inc. (0000933974) (Filer)

      5/30/25 4:15:02 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      5/16/25 4:12:24 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form 10-Q filed by Azenta Inc.

      10-Q - Azenta, Inc. (0000933974) (Filer)

      5/9/25 4:07:49 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AZTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AZTA
    Financials

    Live finance-specific insights

    See more
    • SVP, Gen Counsel & Secretary Starr Ephraim was granted 37,779 units of Common (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      5/27/25 6:30:10 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form 3 filed by new insider Starr Ephraim

      3 - Azenta, Inc. (0000933974) (Issuer)

      5/27/25 6:27:14 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Cornog William L was granted 7,000 units of Common (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      5/20/25 4:07:57 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development

      Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial intelligence (AI) life sciences technology company, to enhance adeno-associated virus (AAV) gene therapy development through a fully integrated sequencing and data analysis solution. This partnership brings together GENEWIZ's industry-leading next-generation sequencing services for AAV gene therapy wi

      5/13/25 4:05:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Amendment: SEC Form SC 13G/A filed by Azenta Inc.

      SC 13G/A - Azenta, Inc. (0000933974) (Subject)

      11/13/24 4:05:02 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Amendment: SEC Form SC 13D/A filed by Azenta Inc.

      SC 13D/A - Azenta, Inc. (0000933974) (Subject)

      11/4/24 8:41:47 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form SC 13G filed by Azenta Inc.

      SC 13G - Azenta, Inc. (0000933974) (Subject)

      10/31/24 11:55:02 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024

      BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 148 $ 151 $ 142 (2) % 4 % Organic growth 4 % Sample Management Solutions $ 81 $ 85 $ 79 (4) % 3 % Multiomics $ 66 $ 66 $ 63 0 % 6 % Diluted EPS Continui

      2/5/25 7:00:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

      NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

      11/19/24 5:56:00 PM ET
      $AZTA
      $CON
      $ENV
      $FLEX
      Industrial Machinery/Components
      Technology
      Medical Specialities
      Health Care
    • Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

      William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

      11/4/24 8:00:00 AM ET
      $AZTA
      $BV
      $LVWR
      Industrial Machinery/Components
      Technology
      Business Services
      Consumer Discretionary
    • AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

      Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P

      9/4/24 8:00:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology